Skip to main content

Table 3 Comparison between liver function results in the studied patients

From: Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

N = 200

At the start of treatment

After 1 month of treatment

At the end of treatment

P-value

ALT

Mean

60.5

51.3

37.2

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

12.3

11.8

7.9

AST

Mean

55.6

42.3

35.7

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

13.2

12.7

10.2

ALP

Mean

285.3

120.6

90.2

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

36.4

24.3

19.5

GGT

Mean

60.7

55.2

25.8

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

17.8

15.5

13.2

Total bilirubin

Mean

2.3

1.5

1.01

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

±SD

0.9

0.8

0.5

Direct bilirubin

Mean

0.9

0.5

0.1

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

0.3

0.1

0.02

Albumin

Mean

2.2

2.3

2.4

P1 = 0.151 NS

P2 = 0.06 NS

P3 = 264 NS

± SD

0.9

0.4

1.2

INR

Mean

1.2

1.09

1.1

P1 = < 0.001 HS

P2 = < 0.001 HS

P3 = < 0.001 HS

± SD

0.2

0.3

0.2

  1. X2: Chi-square test
  2. S: p-value < 0.05 is considered significant
  3. HS: p-value < 0.001 is considered highly significant
  4. P1: refers to the statistical difference between the start of DAA and 1 month after DAA
  5. P2: refers to the statistical difference between the start of DAA and the end of DAA
  6. P3: refers to the statistical difference between 1 month after DAA and the end of DAA